Ultragenyx Pharmaceutical Inc. (RARE) P/E Ratio, ROE & Key Statistics
$16.70NASDAQ: RAREMarket Cap $1.70B
Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)
Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Ultragenyx Pharmaceutical Inc. (RARE), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
-3.31
P/B ratioShare price divided by book value per share.
-4.66
P/S ratioMarket value divided by annual revenue.
2.32
PEG ratioP/E divided by the earnings growth rate.
-0.26
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.
-6.54
EV / RevenueEnterprise value against annual revenue.
3.66
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.
-35.53%
Free cash flow yieldFree cash flow as a percentage of market value.
-29.17%
Profitability
Metric
Value
Gross marginRevenue left after the direct cost of goods sold.
82.88%
Operating marginRevenue left after operating costs.
-64.11%
Net marginRevenue left after every cost, including tax and interest.
-71.78%
Return on equityProfit as a percentage of shareholders’ equity.
213.22%
Return on assetsProfit as a percentage of total assets.
-44.14%
Return on capital employedOperating profit against the capital the business uses.
-58.65%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
2.48
Quick ratioThe same, excluding inventory.
2.34
Cash ratioCash alone against current liabilities.
1.13
Debt to equityTotal borrowings against shareholders’ equity.
-3.15
Debt to assetsTotal borrowings against total assets.
0.83
Interest coverageHow many times operating profit covers the interest bill.
-8.63
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
−$5.83
Book value per shareShareholders’ equity divided by shares outstanding.
−$0.83
Market capitalisationShare price times shares outstanding.
$1.70B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.
$2.68B
Dividend
Metric
Value
Dividend yieldAnnual dividend as a percentage of the share price.
0.00%
Ultragenyx Pharmaceutical Inc. (RARE) statistics — frequently asked questions
What is Ultragenyx Pharmaceutical Inc.'s P/E ratio?
Ultragenyx Pharmaceutical Inc. (RARE) trades on a price-to-earnings ratio of -3.31. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.
What is Ultragenyx Pharmaceutical Inc.'s return on equity?
Ultragenyx Pharmaceutical Inc. (RARE) reports a return on equity of 213.22%, meaning it generated that much profit for every dollar of shareholders' equity.
How much debt does Ultragenyx Pharmaceutical Inc. carry?
Ultragenyx Pharmaceutical Inc. (RARE) has a debt-to-equity ratio of -3.15, which compares total borrowings with shareholders' equity.
What is Ultragenyx Pharmaceutical Inc.'s profit margin?
Ultragenyx Pharmaceutical Inc. (RARE) keeps -71.78% of revenue as net profit after every cost, including tax and interest.